Abstract
Lansoprazole is the second inhibitor of the gastric H+/K+-ATPase to be marketed for the treatment of peptic ulcer disease and reflux oesophagitis. Like omeprazole, lansoprazole is an acid-activated, non-competitive and highly specific inhibitor of the proton pump which causes profound and long-lasting inhibition of acid secretion. In controlled clinical trials, lansoprazole results in more rapid healing of duodenal and gastric ulcers than histamine H2 receptor antagonists. The drug is extremely effective in treating oesophagitis, resistant ulcers and Zollinger-Ellison syndrome when compared with H2 blockers and can be used in combination with amoxycillin or clarithromycin to achieve eradication of Helicobacter pylori. In a number of trials in which proton pump inhibitors (PPIs) have been directly compared, lansoprazole has produced slightly faster rates of healing and pain relief than omeprazole. These marginal advantages may reflect the improved bioavailability of lansoprazole and/or the fact that it has...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
